Prevention of Remifentanil Induced Postoperative Hyperalgesia by Dexmedetomidine via Regulating the Trafficking and Function of Spinal NMDA Receptors as well as PKC and CaMKII Level In Vivo and In Vitro.

Remifentanil-induced secondary hyperalgesia has been demonstrated in both animal experiments and clinical trials. Enhancement of N-methyl-D-aspartate (NMDA) receptor trafficking as well as protein kinase C (PKC) and calmodulin-dependent protein kinase II (CaMKII) have been reported to be involved in...

Full description

Bibliographic Details
Main Authors: Yuan Yuan, Zhe Sun, Yi Chen, Yuxin Zheng, Ke-Liang Xie, Ying He, Zhifen Wang, Guo-Lin Wang, Yong-Hao Yu
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5300256?pdf=render
id doaj-fbc13101e049447ab7d7b93182626eaa
record_format Article
spelling doaj-fbc13101e049447ab7d7b93182626eaa2020-11-24T21:40:45ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01122e017134810.1371/journal.pone.0171348Prevention of Remifentanil Induced Postoperative Hyperalgesia by Dexmedetomidine via Regulating the Trafficking and Function of Spinal NMDA Receptors as well as PKC and CaMKII Level In Vivo and In Vitro.Yuan YuanZhe SunYi ChenYuxin ZhengKe-Liang XieYing HeZhifen WangGuo-Lin WangYong-Hao YuRemifentanil-induced secondary hyperalgesia has been demonstrated in both animal experiments and clinical trials. Enhancement of N-methyl-D-aspartate (NMDA) receptor trafficking as well as protein kinase C (PKC) and calmodulin-dependent protein kinase II (CaMKII) have been reported to be involved in the induction and maintenance of central sensitization. In the current study, it was demonstrated that dexmedetomidine could prevent remifentanil-induced hyperalgesia (RIH) via regulating spinal NMDAR-PKC-Ca2+/ CaMKII pathway in vivo and in vitro. We firstly investigated the effect of dexmedetomidine, a highly selective α2-adrenergic receptor agonist, on mechanical and thermal hyperalgesia using a rat model of RIH. NMDA receptor subunits (NR1, NR2A and NR2B) expression and membrane trafficking as well as PKC and CaMKII expression in spinal cord L4-L5 segments were measured by Western blot analysis. The expression of NMDA receptor subunits (NR1, NR2A and NR2B) were also detected by immunohistochemistry. Further more, the effect of dexmedetomidine on NMDA receptor current amplitude and frequency in spinal cord slices were investigated by whole-cell patch-clamp recording. We found that remifentail infusion at 1.2 μg.kg-1.min-1 for 90 min caused mechanical and thermal hyperalgesia, up-regulated NMDA receptor subunits NR1 and NR2B expression in both membrane fraction and total lysate as well as increased PKC and CaMKII expression in spinal cord dorsal horn. Subcutaneously injection of dexmedetomidine at the dose of 50 μg/kg at 30 min before plantar incision significantly attenuated remifentanil-induced mechanical and thermal hyperalgesia from 2 h to 48 h after infusion, and this was associated with reversal of up-regulated NR1 and NR2B subunits in both membrane fraction and total lysate as well as increased PKC and CaMKII expression in spinal cord dorsal horn. Furthermore, remifentanil incubation increased amplitude and frequency of NMDA receptor-induced current in dorsal horn neurons, which was dose-dependently attenuated by dexmedetomidine. These results suggest that dexmedetomidine can significantly ameliorate RIH via modulating the expression, membrane trafficking and function of NMDA receptors as well as PKC and CaMKII level in spinal dorsal horn, which present useful insights into the mechanistic action of dexmedetomidine as a potential anti-hyperalgesic agents for treating RIH.http://europepmc.org/articles/PMC5300256?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Yuan Yuan
Zhe Sun
Yi Chen
Yuxin Zheng
Ke-Liang Xie
Ying He
Zhifen Wang
Guo-Lin Wang
Yong-Hao Yu
spellingShingle Yuan Yuan
Zhe Sun
Yi Chen
Yuxin Zheng
Ke-Liang Xie
Ying He
Zhifen Wang
Guo-Lin Wang
Yong-Hao Yu
Prevention of Remifentanil Induced Postoperative Hyperalgesia by Dexmedetomidine via Regulating the Trafficking and Function of Spinal NMDA Receptors as well as PKC and CaMKII Level In Vivo and In Vitro.
PLoS ONE
author_facet Yuan Yuan
Zhe Sun
Yi Chen
Yuxin Zheng
Ke-Liang Xie
Ying He
Zhifen Wang
Guo-Lin Wang
Yong-Hao Yu
author_sort Yuan Yuan
title Prevention of Remifentanil Induced Postoperative Hyperalgesia by Dexmedetomidine via Regulating the Trafficking and Function of Spinal NMDA Receptors as well as PKC and CaMKII Level In Vivo and In Vitro.
title_short Prevention of Remifentanil Induced Postoperative Hyperalgesia by Dexmedetomidine via Regulating the Trafficking and Function of Spinal NMDA Receptors as well as PKC and CaMKII Level In Vivo and In Vitro.
title_full Prevention of Remifentanil Induced Postoperative Hyperalgesia by Dexmedetomidine via Regulating the Trafficking and Function of Spinal NMDA Receptors as well as PKC and CaMKII Level In Vivo and In Vitro.
title_fullStr Prevention of Remifentanil Induced Postoperative Hyperalgesia by Dexmedetomidine via Regulating the Trafficking and Function of Spinal NMDA Receptors as well as PKC and CaMKII Level In Vivo and In Vitro.
title_full_unstemmed Prevention of Remifentanil Induced Postoperative Hyperalgesia by Dexmedetomidine via Regulating the Trafficking and Function of Spinal NMDA Receptors as well as PKC and CaMKII Level In Vivo and In Vitro.
title_sort prevention of remifentanil induced postoperative hyperalgesia by dexmedetomidine via regulating the trafficking and function of spinal nmda receptors as well as pkc and camkii level in vivo and in vitro.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2017-01-01
description Remifentanil-induced secondary hyperalgesia has been demonstrated in both animal experiments and clinical trials. Enhancement of N-methyl-D-aspartate (NMDA) receptor trafficking as well as protein kinase C (PKC) and calmodulin-dependent protein kinase II (CaMKII) have been reported to be involved in the induction and maintenance of central sensitization. In the current study, it was demonstrated that dexmedetomidine could prevent remifentanil-induced hyperalgesia (RIH) via regulating spinal NMDAR-PKC-Ca2+/ CaMKII pathway in vivo and in vitro. We firstly investigated the effect of dexmedetomidine, a highly selective α2-adrenergic receptor agonist, on mechanical and thermal hyperalgesia using a rat model of RIH. NMDA receptor subunits (NR1, NR2A and NR2B) expression and membrane trafficking as well as PKC and CaMKII expression in spinal cord L4-L5 segments were measured by Western blot analysis. The expression of NMDA receptor subunits (NR1, NR2A and NR2B) were also detected by immunohistochemistry. Further more, the effect of dexmedetomidine on NMDA receptor current amplitude and frequency in spinal cord slices were investigated by whole-cell patch-clamp recording. We found that remifentail infusion at 1.2 μg.kg-1.min-1 for 90 min caused mechanical and thermal hyperalgesia, up-regulated NMDA receptor subunits NR1 and NR2B expression in both membrane fraction and total lysate as well as increased PKC and CaMKII expression in spinal cord dorsal horn. Subcutaneously injection of dexmedetomidine at the dose of 50 μg/kg at 30 min before plantar incision significantly attenuated remifentanil-induced mechanical and thermal hyperalgesia from 2 h to 48 h after infusion, and this was associated with reversal of up-regulated NR1 and NR2B subunits in both membrane fraction and total lysate as well as increased PKC and CaMKII expression in spinal cord dorsal horn. Furthermore, remifentanil incubation increased amplitude and frequency of NMDA receptor-induced current in dorsal horn neurons, which was dose-dependently attenuated by dexmedetomidine. These results suggest that dexmedetomidine can significantly ameliorate RIH via modulating the expression, membrane trafficking and function of NMDA receptors as well as PKC and CaMKII level in spinal dorsal horn, which present useful insights into the mechanistic action of dexmedetomidine as a potential anti-hyperalgesic agents for treating RIH.
url http://europepmc.org/articles/PMC5300256?pdf=render
work_keys_str_mv AT yuanyuan preventionofremifentanilinducedpostoperativehyperalgesiabydexmedetomidineviaregulatingthetraffickingandfunctionofspinalnmdareceptorsaswellaspkcandcamkiilevelinvivoandinvitro
AT zhesun preventionofremifentanilinducedpostoperativehyperalgesiabydexmedetomidineviaregulatingthetraffickingandfunctionofspinalnmdareceptorsaswellaspkcandcamkiilevelinvivoandinvitro
AT yichen preventionofremifentanilinducedpostoperativehyperalgesiabydexmedetomidineviaregulatingthetraffickingandfunctionofspinalnmdareceptorsaswellaspkcandcamkiilevelinvivoandinvitro
AT yuxinzheng preventionofremifentanilinducedpostoperativehyperalgesiabydexmedetomidineviaregulatingthetraffickingandfunctionofspinalnmdareceptorsaswellaspkcandcamkiilevelinvivoandinvitro
AT keliangxie preventionofremifentanilinducedpostoperativehyperalgesiabydexmedetomidineviaregulatingthetraffickingandfunctionofspinalnmdareceptorsaswellaspkcandcamkiilevelinvivoandinvitro
AT yinghe preventionofremifentanilinducedpostoperativehyperalgesiabydexmedetomidineviaregulatingthetraffickingandfunctionofspinalnmdareceptorsaswellaspkcandcamkiilevelinvivoandinvitro
AT zhifenwang preventionofremifentanilinducedpostoperativehyperalgesiabydexmedetomidineviaregulatingthetraffickingandfunctionofspinalnmdareceptorsaswellaspkcandcamkiilevelinvivoandinvitro
AT guolinwang preventionofremifentanilinducedpostoperativehyperalgesiabydexmedetomidineviaregulatingthetraffickingandfunctionofspinalnmdareceptorsaswellaspkcandcamkiilevelinvivoandinvitro
AT yonghaoyu preventionofremifentanilinducedpostoperativehyperalgesiabydexmedetomidineviaregulatingthetraffickingandfunctionofspinalnmdareceptorsaswellaspkcandcamkiilevelinvivoandinvitro
_version_ 1725924785387470848